IKIsil Kasapoglu

Isil Kasapoglu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isil Kasapoglu has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Uterus‐Preserving Laparoscopic Technique for Cervicovaginal Agenesis With Functional Uterine Remnants

    by Kiper Aslan, Isil Kasapoglu, Bahadir Kosan, Gürkan Uncu

    Background: Cervicovaginal agenesis with functional uterine remnants is a rare Müllerian anomaly that may cause obstructed menstrual flow, pelvic pain, haematometra, haematosalpinx and endometriosis. Uterus‐preserving reconstruction is challenging because it requires both neovaginal creation and durable uterine drainage. Aims: To describe a uterus‐preserving laparoscopic technique combining peritoneal pull‐down neovaginoplasty with catheter‐guided uterovaginal anastomosis in patients with cervicovaginal agenesis and obstructed functional uterine remnants. Materials and Methods: Seven patients with cervicovaginal agenesis and functional uterine remnants underwent laparoscopic reconstruction between 2019 and 2024. The procedure included laparoscopic‐guided vesicorectal dissection, peritoneal pull‐down neovaginoplasty, opening and drainage of the obstructed uterine remnant, intrauterine Foley catheter placement and circumferential uterovaginal anastomosis. In patients with bilateral remnants, cavity unification was performed before anastomosis. Postoperative mould use and intrauterine catheterisation were used to maintain patency during healing. Results: Menstrual drainage was restored in all patients. Office hysteroscopy confirmed a patent uterovaginal anastomosis and accessible endometrial cavity. No intraoperative bladder, rectal, ureteric or vascular complications occurred. One patient underwent two unsuccessful frozen embryo transfer attempts. One patient required hysterectomy for recurrent pelvic inflammatory disease, with preservation of the neovagina. No late stenosis was observed during available follow‐up. Discussion: This technique may provide a feasible uterus‐preserving approach for selected patients with cervicovaginal agenesis and functional uterine remnants. However, the presence of an accessible cavity does not prove normal biological uterine function, implantation potential or pregnancy safety. The findings should be interpreted with caution because of the small sample size and limited reproductive follow‐up. Conclusion: Laparoscopic peritoneal pull‐down neovaginoplasty combined with catheter‐guided uterovaginal anastomosis may restore menstrual drainage and anatomical patency in carefully selected patients. Further multicentre experience with objective imaging, hysteroscopic follow‐up and reproductive outcome data is required to assess fertility potential, pregnancy safety and long‐term durability.

  • Uterin Myomların Yönetimi

    by Bahadır Koşan, Işıl Kasapoğlu

  • Effects of Cumulus Cell Extracellular Matrix–Assisted Sperm Preparation Protocols on In Vitro Sperm Quality

    by Sabina Aghayeva, Talha Yasin Durdu, Cihan Çakır, Kiper Aslan, Işıl Kasapoğlu, Duygu Gök Yurtseven

    This study aimed to determine the effects of adding cumulus cell extracellular matrix (CCECM) to the culture medium used in sperm preparation techniques for assisted reproductive treatments (ART) on routine sperm parameters, fertilization capacity, and sperm DNA fragmentation, and to compare sperm separation protocols. Ejaculate samples from 30 normozoospermic male patients and cumulus–oocyte complexes collected from their spouses were included. Each semen sample was divided into five equal volumes and allocated to five groups: control, density gradient (DG), density gradient plus cumulus cell extracellular matrix (DG+K), swim-up (SU), and swim-up plus cumulus cell extracellular matrix (SU+K). The results showed that sperm concentration was markedly lower in all experimental groups than in the control group, with the decrease reaching statistical significance, particularly in the swim-up group. Motility was highest in the SU+K group and was also significantly increased in the DG+K and SU groups. In contrast, the TPMSS value decreased significantly in the SU and SU+K groups. No marked differences were observed among the groups in terms of morphology. Viability increased notably in the CCECM-supplemented groups, and this increase remained significant across all experimental groups compared with the control group. ARIC scores, reflecting acrosomal reaction capacity, were significantly higher in the DG+K and SU+K groups. Moreover, DFI values, indicating DNA damage, were significantly lower in these two groups, suggesting that CCECM supplementation may help preserve sperm DNA integrity. Adding CCECM to the culture medium used in sperm washing improved sperm quality and efficiency, particularly with the swim-up method. We believe this approach may be a feasible option for treating male infertility within assisted reproductive technologies (ART).

  • Considering its mechanism of action it may be logical to choose letrozole as an initial option for endometrium preparation before vitrified‐warmed embryo transfer

    by Gercek Aydin, Kiper Aslan, Merve Arac, Elif Ergin, Isil Kasapoglu, Gurkan Uncu

    Aim: To assess the efficacy of letrozole and programmed hormone replacement therapy (HRT) cycles in terms of obstetric outcomes for women undergoing a single vitrified‐warmed blastocyst embryo transfer (SVBT). Methods: This study is a retrospective study conducted in a private IVF (in vitro fertilization) clinic. A total of 324 FET cycles (letrozole group = 183, HRT = 141), consisting of primary infertile patients aged <40 years, were enrolled. The cycle characteristics, pregnancy results, and perinatal parameters were recorded. The primary outcomes of this study are pregnancy and miscarriage rates, live birth rates, whereas hypertensive disease of pregnancy (HDP), intrauterine growth restriction (IUGR) and preterm birth are the secondary outcomes. Results: Positive β‐HCG rates were 53% (97/183) versus 61% (86/141), whereas clinical pregnancy rates were 47% (86/183) versus 51.1% (72/141) for the letrozole and HRT groups, respectively. For clinical miscarriage, the results were 6.5% (12/183) for letrozole versus 15.6% (22/141) for HRT groups, which were statistically significant. For live birth rate (LBR), letrozole was found to be slightly better compared to HRT 40.4% (74/183) versus 35.5% (50/141). Considering the perinatal outcomes, the parameters were comparable between the groups. Conclusions: In terms of perinatal outcomes and IVF success, letrozole was not found to be inferior to HRT. Letrozole can be utilized as a safe and effective agent, even as a first‐line treatment, given the potential benefits offered by its mechanism of action and being a reasonable option for both ovulatory and unovulatory patients.


  • Open Access

    Does Serum Delta FSH Level Provided with High Starting Dose FSH Differ Among Various Ovarian Responses?

    by Işıl Kasapoğlu, Kiper Aslan, Cihan Çakır, Göktan Kuşpınar, Berrin Avcı, Berke Oral, Gürkan Uncu

    The objective of this study is to evaluate whether serum delta FSH levels (the percentage difference of serum FSH between antagonist starting day and basal serum FSH level) differ between patients with different COH responses (poor, suboptimal response and normoresponders) who stimulated with a high (300 IU) fixed recombinant FSH dose during flexible antagonist cycles. This study is a retrospective cross sectional cohort study conducted in a tertiary ART Center. 122 women were evaluated, of which, 51 were poor responders, 52 had suboptimal response and 19 had normal response. The primary outcome is to evaluate the spot serum FSH levels on the first day of GnRH antagonist dose administration and the delta FSH levels between groups. Basal serum FSH levels differed significantly between (7[5.2-8.6], 5.7[4.6-7.2], 4.8[4.1-5.3] poor, suboptimal and normoresponders respectively; p

  • Open Access

    The Effect of the Gonadotropin Dose Increment During Controlled Ovarian Hyperstimulation on Live Birth Rates of POSEIDON Group 3-4 Patients

    by Kiper Aslan, Işıl Kasapoğlu, Cagatay Mesut, Tansu Bahar Gurbuz, Cihan Çakır, Berrin Avcı, Gürkan Uncu

    This retrospective study seeks to explore whether modifying the gonadotropin dose in cases of poor ovarian response during controlled ovarian hyperstimulation contributes to improved live birth rates in Poseidon Group 3-4 patients. The study took place at a tertiary level university. The electronic database spanning 2012-2021 was scrutinized to identify patients with diminished ovarian reserve (DOR) who underwent intra-cytoplasmic sperm injection – embryo transfer (ICSI-ET). Diminished ovarian reserve was determined using the POSEIDON criteria. Patients were categorized into two groups based on whether dose adjustment was implemented during the initial ultrasound assessment in controlled ovarian hyperstimulation (COH). There were 188 patients in the dose adjustment (DA) group and 310 patients in the fixed-dose (FD) group. The demographic parameters were similar between the groups. The started gonadotropin dose was similar in both groups (300 IU). The median dose adjustment on the first control was +75 IU in the DA group. The follicle output rates, follicle to oocyte indexes, and the embryology parameters were comparable between the groups. The positive pregnancy rate was 19.7% (36/188) in the DA group vs. 19.1% (61/310) in the FD Group (p=0.4). The primary outcome of the study; live birth rates were 12% in the DA group vs. 9% in the FD group, and the results were statistically similar (p=0.3). Our research revealed that adjusting the gonadotropin dose in cases of inadequate ovarian response during COH results in comparable live birth rates to those observed in the fixed-dose group. For patients exhibiting an inadequate response, dose adjustment may be deemed necessary.

  • Open Access

    Additional Daily Intramuscular Progesterone for Luteal Phase Support does not Improve Live Birth Rates of Programmed Frozen-Thawed Embryo Transfer Cycles

    by Kiper Aslan, Işıl Kasapoğlu, Tugba Akkok, Cihan Çakır, Berrin Avcı, Gürkan Uncu

    This retrospective cohort study aims to investigate whether additional daily intramuscular progesterone (IMP) for luteal phase support improves live birth rates of programmed frozen-thawed embryo transfer (FET) cycles. The study was conducted at a tertiary level university hospital assisted reproductive technology (ART) center between January 2014 and Jan 2021. Six hundred four infertile patients with single-day 5-6 frozen-thawed blastocyst embryo transfer were enrolled in the study. All patients received either 8% micronized vaginal gel or vaginal progesterone capsules for luteal phase support. Intramuscular progesterone was added to vaginal progesterone depending on the in vitro fertilization (IVF) specialist’s choice. Luteal phase support (LPS) was started 6 days before transfer in frozen-thawed cycles and continued until the end of the first trimester. Cycles were compared depending on vaginal progesterone types (8% gel vs. capsule) and the presence of intramuscular progesterone. The primary outcome was the live birth rate. A total of 604 FET cycles were enrolled. Using 8% micronized progesterone or progesterone capsules did not change the live birth rates (24% vs. 25.9%). As the main result, intramuscular progesterone support with vaginal progesterone compared with only vaginal progesterone did not improve the live birth results (22% vs. 24%). In conclusion, this study demonstrated that routine IMP progesterone given in combination with vaginal progesterone does not improve ART outcomes. This combination may be beneficial in a selective population with a monitored luteal phase. Using any form of vaginal progesterone alone is adequate for LPS.